These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 1991366)
21. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study. Olsson AG; Ruhn G; Erikson U J Intern Med; 1990 Jun; 227(6):381-90. PubMed ID: 2351925 [TBL] [Abstract][Full Text] [Related]
22. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Brown BG; Bardsley J; Poulin D; Hillger LA; Dowdy A; Maher VM; Zhao XQ; Albers JJ; Knopp RH Am J Cardiol; 1997 Jul; 80(2):111-5. PubMed ID: 9230143 [TBL] [Abstract][Full Text] [Related]
23. Role of risk factor management in progression and regression of coronary and femoral artery atherosclerosis. Glueck CJ Am J Cardiol; 1986 May; 57(14):35G-41G. PubMed ID: 3521250 [TBL] [Abstract][Full Text] [Related]
25. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627 [TBL] [Abstract][Full Text] [Related]
26. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia. Kuo PT; Hayase K; Kostis JB; Moreyra AE Circulation; 1979 Feb; 59(2):199-211. PubMed ID: 215338 [TBL] [Abstract][Full Text] [Related]
27. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Zhao XQ; Brown BG; Hillger L; Sacco D; Bisson B; Fisher L; Albers JJ Circulation; 1993 Dec; 88(6):2744-53. PubMed ID: 8252687 [TBL] [Abstract][Full Text] [Related]
28. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Salonen R; Nyyssönen K; Porkkala E; Rummukainen J; Belder R; Park JS; Salonen JT Circulation; 1995 Oct; 92(7):1758-64. PubMed ID: 7671358 [TBL] [Abstract][Full Text] [Related]
29. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Brown BG; Zambon A; Poulin D; Rocha A; Maher VM; Davis JW; Albers JJ; Brunzell JD Am J Cardiol; 1998 Feb; 81(4A):52B-59B. PubMed ID: 9526815 [TBL] [Abstract][Full Text] [Related]
30. Protection of myocardium by the compensatory mechanism of coronary collaterals after total occlusion of major coronary arteries shown in patients with familial hypercholesterolemia. Kuo PT; Kostis JB; Moreyra AE Am Heart J; 1982 Jul; 104(1):36-43. PubMed ID: 7090984 [TBL] [Abstract][Full Text] [Related]
31. Effect of lovastatin or niacin combined with colestipol and regression of coronary atherosclerosis. Brown BG Eur Heart J; 1992 Jul; 13 Suppl B():17-20. PubMed ID: 1644095 [TBL] [Abstract][Full Text] [Related]
32. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Malloy MJ; Kane JP; Kunitake ST; Tun P Ann Intern Med; 1987 Nov; 107(5):616-23. PubMed ID: 3662275 [TBL] [Abstract][Full Text] [Related]
33. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G; Erikson U; Olsson AG; Bergstrand L; Hådell K; Johansson J; Kaijser L; Lassvik C; Mölgaard J; Nilsson S Am J Cardiol; 1994 Nov; 74(9):875-83. PubMed ID: 7977117 [TBL] [Abstract][Full Text] [Related]
34. Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy. Zambon A; Brown BG; Hokanson JE; Motulsky AG; Brunzell JD J Intern Med; 2006 Apr; 259(4):401-9. PubMed ID: 16594908 [TBL] [Abstract][Full Text] [Related]
35. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Azen SP; Qian D; Mack WJ; Sevanian A; Selzer RH; Liu CR; Liu CH; Hodis HN Circulation; 1996 Nov; 94(10):2369-72. PubMed ID: 8921775 [TBL] [Abstract][Full Text] [Related]
36. Study bolsters case against cholesterol. Roberts L Science; 1987 Jul; 237(4810):28-9. PubMed ID: 3603009 [No Abstract] [Full Text] [Related]
37. Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease. Kuo PT; Wilson AC; Kostis JB; Moreyra AE Am J Cardiol; 1986 Jun; 57(16):43H-48H. PubMed ID: 3524177 [TBL] [Abstract][Full Text] [Related]
39. Comparison of hypocholesterolemic activities of the bile acid sequestrants cholestyramine and colestipol hydrochloride in cholesterol fed SEA quail. Day CE Artery; 1990; 17(5):281-8. PubMed ID: 2396902 [TBL] [Abstract][Full Text] [Related]
40. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. Post Coronary Artery Bypass Graft Trial Investigators N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]